Polo-like Kinase 4 inhibition: A strategy for cancer therapy?

Andrew J. Holland, Don W. Cleveland

Research output: Contribution to journalShort survey

Abstract

In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4) inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant therapeutic target.

Original languageEnglish (US)
Pages (from-to)151-153
Number of pages3
JournalCancer cell
Volume26
Issue number2
DOIs
StatePublished - Aug 11 2014

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'Polo-like Kinase 4 inhibition: A strategy for cancer therapy?'. Together they form a unique fingerprint.

  • Cite this